HealthQuill adults
A majority of clinical research on adult Attention Deficit Hyperactivity Disorder (ADHD) suffers from serious methodological shortcomings, making it difficult to use the results in practice, according to researchers from the University of Copenhagen and the University of SĂŁo Paulo.
Drugs Health Research

Researchers find serious flaws in clinical trials with adult ADHD patients

HQ Team July 2, 2025: A majority of clinical research on adult Attention Deficit Hyperactivity Disorder (ADHD) suffers from serious methodological shortcomings, making.

Read More
Johnson & Johnson’s immune disorder drug has been approved by the US Food and Drug Administration for the treatment of generalised myasthenia gravis (gMG) — a rare disease that causes muscle weakness and affects daily activities like chewing, swallowing, speaking, and breathing.
Drugs Health Pharma

US regulator approves Johnson & Johnson’s immune disorder drug

HQ Team April 30, 2025: Johnson & Johnson’s immune disorder drug has been approved by the US Food and Drug Administration for the.

Read More
The US Food and Drug Administration approved AstraZeneca Plc’s Fasenra for treatment in adult patients with a rare inflammation of blood vessels.
Drugs Health Pharma

AstraZeneca’s rare disease drug Fasenra gets US regulator’s nod

The US Food and Drug Administration approved AstraZeneca Plc’s Fasenra for treatment in adult patients with a rare inflammation of blood vessels.

Read More
allergy
Drugs Health Pharma

FDA approves Genetech’s Xolair injection for severe food allergies

HQ Team February 19, 2024: The Food and Drug Administration (FDA) has approved Genetech’s Xolair (omalizumab) injection for severe food allergies in certain adults.

Read More